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Introduction
The aggregation and subsequent cerebral accumulation of the 
amyloid-β (Aβ) peptide is a key initiating factor in Alzheimer’s dis-
ease (AD), where Aβ aggregation begins approximately 15 years prior 
to the onset of cognitive symptoms (1, 2). In addition to extracellular 
Aβ aggregation and subsequently intraneuronal tau accumulation, 
decreased glucose metabolism also occurs in regions prone to AD 
pathology during this presymptomatic period. Although both Aβ 
and tau are central to AD pathogenesis, it is unclear whether glu-
cose dysregulation is an initiator of AD pathology, a secondary con-
sequence of neuronal dysfunction due to Aβ and tau deposition, or 
both. Recent epidemiological studies demonstrate that individuals 
with type 2 diabetes (T2DM) are 2–4 times more likely to develop 
AD (3–5), individuals with elevated blood glucose levels are at an 
increased risk to develop dementia (5), and those with elevated 
blood glucose levels have a more rapid conversion from mild cog-
nitive impairment (MCI) to AD (6), suggesting that disrupted glu-
cose homeostasis could play a more causal role in AD pathogenesis. 
Although several prominent features of T2DM, including increased 
insulin resistance and decreased insulin production, are at the fore-
front of AD research (7–10), questions regarding the effects of elevat-
ed blood glucose independent of insulin resistance on AD pathology 
remain largely unexplored. In order to investigate the potential role 
of glucose metabolism in AD, we combined glucose clamps and in 
vivo microdialysis as a method to measure changes in brain metabo-
lites in awake, freely moving mice during a hyperglycemic challenge. 
Our findings suggest that acute hyperglycemia raises interstitial 
fluid (ISF) Aβ levels by altering neuronal activity, which increases 
Aβ production. Since cerebral glucose metabolism is tightly linked 
to neuronal activity (11, 12) and elevated neuronal activity increases 
Aβ production (13–15), we explored the role of inward rectifying, 
ATP-sensitive potassium (KATP) channels as one mechanism link-
ing glucose metabolism, neuronal excitability, and ISF Aβ. Our data 
suggests that KATP channels can mediate the response of hippocam-
pal neurons to elevated blood glucose levels by coupling changes in 
metabolism with neuronal activity and ISF Aβ.
Results and Discussion
The levels of soluble, monomeric Aβ in the brain determine the 
likelihood that Aβ will aggregate and lead to toxicity (13, 16). 
Therefore, we first sought to assess the acute effects of hypergly-
cemia on the concentration of Aβ within the brain ISF. We coupled 
glucose clamps (17) with in vivo microdialysis (18) in APPswe/
PS1ΔE9 (APP/PS1) mice that were 3 months old, an age prior to 
the onset of brain Aβ deposition (19). These techniques allowed 
us to acutely manipulate systemic blood glucose levels in awake, 
freely moving mice while simultaneously assessing dynamic 
changes in brain metabolites in hippocampal ISF. During a 4-hour 
glucose clamp, blood glucose levels were raised from 93.8 ± 8.2 
mg/dl to 204.2 ± 4.5 mg/dl, representing a 2.2-fold increase from 
baseline in 3-month-old APP/PS1 mice (Figure 1A). A comparable 
effect was seen in WT mice receiving the same metabolic chal-
lenge (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI79742DS1). This elevation 
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Figure 1. Hyperglycemia increases ISF 
glucose and Aβ levels in the APP/PS1 hip-
pocampus in vivo. (A) Blood glucose levels 
in 3-month-old APP/PS1 mice (n = 6–8 mice/
group) during fasted baseline and hypergly-
cemic clamp. (B) ISF glucose levels increased 
from 0.158 ± 0.004 to 0.306 ± 0.011 mmol/l 
during hyperglycemia in 3-month-old APP/
PS1 mice (n = 6–8 mice/group). (C) Hyper-
glycemia increased ISF Aβ levels by 24.5% ± 
3.8% in 3-month-old APP/PS1 mice during 
and after clamp (n = 6–7 mice/group). (D) ISF 
Aβ correlates with ISF glucose during hyper-
glycemia (n = 6 mice, Pearson’s r = 0.6032;  
P < 0.01). (E) ISF glucose levels increased 
from 0.153 ± 0.003 to 0.397 ± 0.0149 mmol/l 
during hyperglycemia in 18-month-old APP/
PS1 mice (n = 6–7 mice/group). (F) Hypergly-
cemia increased ISF Aβ levels by 38.8% ± 
5.3% in 18-month-old APP/PS1 mice, during 
and after glucose clamps (n = 6–7 mice/
group). (G) Hyperglycemia increases ISF 
lactate, a marker of neuronal activity (n = 7 
mice/group). (H) Compound E decreases ISF 
Aβ during hyperglycemia and does not alter 
ISF Aβ half-life, demonstrating hyperglyce-
mia alters Aβ production, not Aβ clearance. 
Data represent mean ± SEM. Significance 
denoted *P < 0.05, **P < 0.01, and  
***P < 0.001 using 2-way ANOVA (C and F)  
or Student’s t tests (A, B, E, G, and H).
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PS1 mice where blood glucose was clamped 
between 150–200 mg/dl, increases in blood 
glucose raised ISF glucose 2.6-fold from base-
line (Figure 1E). Hyperglycemia significantly 
increased hippocampal ISF Aβ by 38.8% ± 
5.3%, with a maximal effect of 45.6% ± 9.0%, 
which persisted after euglycemia was restored 
(Figure 1F). The hyperglycemia-dependent 
increase in ISF Aβ levels was 1.6-fold higher in 
18-month-old mice compared with 3-month-
old mice, demonstrating that older mice with 
significant plaque pathology respond differ-
entially to a hyperglycemic insult. Previous 
studies demonstrated that increased synaptic 
activity drives Aβ release from an endocytic 
pool in vivo, resulting in an increase in ISF Aβ 
but not total tissue Aβ (14, 15, 18). We found 
that hyperglycemia increased ISF Aβ specifi-
cally, while the total amount of Aβ40 and Aβ42 
within the brain did not change (Supplemental 
Figure 3). Due to the astrocyte neuron lactate shuttle, extracellular 
lactate can be used as a marker of neuronal activity, and previous 
work shows that it increases in concert with ISF Aβ (13, 20–22). ISF 
lactate increased during glucose clamps, suggesting hyperglyce-
mia increases both neuronal activity and ISF Aβ (Figure 1G and 
Supplemental Figure 4). To determine whether elevations in ISF 
Aβ were due to increased production or decreased clearance of Aβ, 
we administered compound E, a potent gamma secretase inhibi-
tor, concurrently with hyperglycemia as a means to abolish Aβ pro-
duction and to measure the rate of ISF Aβ clearance. This showed 
that the rate of ISF Aβ clearance did not differ in the presence ver-
sus the absence of hyperglycemia, illustrating that the hypergly-
cemia-induced increase in ISF Aβ levels is not due to a significant 
in blood glucose resulted in a 1.9-fold increase in hippocampal 
ISF glucose (Figure 1B). ISF Aβ increased by 24.5% ± 3.8% during 
the hyperglycemia challenge, an effect that was sustained after 
euglycemia was restored subsequent to the glucose clamp (Fig-
ure 1C). While the effects of glucose on ISF Aβ were variable, ISF 
glucose correlated with ISF Aβ during hyperglycemia (Pearson’s 
r = 0.6032; P < 0.01), demonstrating that hippocampal Aβ concen-
trations are likely modulated by blood glucose levels (Figure 1D).
Hypothesizing that the presence of Aβ aggregation into amy-
loid plaques and oligomers promotes localized injury and affects 
the brain’s response to hyperglycemia, we altered blood glucose 
levels in mice with significant Aβ plaque burden (Supplemen-
tal Figure 2). Using the same approach in 18-month-old APP/
Figure 2. Modulation of hippocampal KATP channels 
affects ISF Aβ and lactate in vivo. (A) Gliben-
clamide, a KATP antagonist, was given via reverse 
microdialysis and increased ISF Aβ in a dose-
dependent manner, with a maximal increase of 
36.2% ± 3.2% at 100 μM. The left panel represents 
a time course of the 100 μM dose, while the right 
demonstrates the dose-dependent effects of 
glibenclamide. (B) ISF lactate increased in a dose-
dependent manner, with a maximal increase of 
73.3-5% ± 19.8%. The left panel represents a time 
course of the 100 μM dose, while the right illus-
trates the dose-dependent effects of glibenclamide. 
(C) Diazoxide, a KATP agonist, did not alter ISF Aβ 
levels. The left panel demonstrates a time course 
of the 300 μM dose of diazoxide, where the right 
shows that diazoxide does not affect ISF Aβ at any 
dose. (D) Diazoxide (300 μM) decreased ISF lactate 
by 22.5% ± 4.3% after administration. The left 
panel demonstrates the time course of the  
300 μM dose of diazoxide, while the right shows a 
dose response of diazoxide. Data represent mean 
± SEM. For all analyses, n = 5–7 mice/group per 
glibenclamide dose and n = 4–5 mice/group per 
diazoxide dose. *P < 0.05, **P < 0.01, ***P < 0.001 
using a 1-way ANOVA.
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and hyperpolarizing cells (Figure 2, C and D, and Supplemental 
Figure 5). Although no overall change in ISF Aβ was observed (Fig-
ure 2C and Supplemental Figure 5A), diazoxide decreased ISF lac-
tate by 22.5% ± 4.3%, suggesting an inhibitory effect on neuronal 
activity (Figure 2D). This finding is consistent with previous work, 
demonstrating that diazoxide decreased action-potential frequen-
cy and calcium influx in cultured cortical neurons (26). Together, 
our findings suggest that KATP channels alter cellular excitability 
within the hippocampus and that increased cellular excitability via 
KATP channel activation leads to increased ISF Aβ.
To determine whether increases in ISF Aβ during hyperglyce-
mia were due to KATP channels, we investigated whether opening 
KATP channels prevented increases in ISF Aβ during hyperglycemia. 
Diazoxide was infused into the hippocampus via reverse microdi-
alysis prior to and during hyperglycemia in 18-month-old APP/PS1 
mice. ISF Aβ levels did not significantly change prior to and during 
hyperglycemia in the presence of diazoxide (Figure 3A). In contrast, 
hyperglycemia alone resulted in a 38.8% ± 5.3% elevation in ISF Aβ, 
demonstrating that diazoxide blocks the increase in ISF Aβ during 
hyperglycemia (Figure 3A). Using ISF lactate levels as a measure of 
neuronal activity, diazoxide treatment blocked the hyperglycemia-
dependent increase in ISF lactate levels (Figure 3B). Taken together, 
these findings demonstrate that KATP channel activation mediates 
the response of hippocampal neurons to elevated glucose levels by 
coupling metabolism with neuronal activity and ISF Aβ.
By combining glucose clamps with in vivo microdialysis, 
we were able to modulate blood glucose levels in awake, free-
ly moving APP/PS1 mice while simultaneously investigating 
slowing of Aβ clearance (Figure 1H). Since both T2DM and AD are 
diseases of aging and Aβ deposition begins about 15 years prior to 
the onset of dementia due to AD, these findings suggest that poor 
glycemic control during a presymptomatic period could increase 
basal neuronal activity, drive Aβ production/release, and instigate 
or exacerbate Aβ deposition.
Elevated extracellular glucose levels can evoke rapid changes 
in neuronal excitability through KATP channels (23, 24). KATP chan-
nels are hetero-octameric proteins composed of 4 inner pore-
forming subunits (Kir6.1 or Kir6.2) and 4 sulfonylurea receptor 
(SUR) subunits. Increased glucose concentrations lead to eleva-
tions in intracellular ATP, causing KATP channel closure, mem-
brane depolarization, and increased cellular excitability. Although 
best described for their role in insulin secretion in pancreatic β 
cells, KATP channels are found on both neurons and astrocytes (25) 
and can couple cellular metabolism with neuronal activity. To 
investigate the role of KATP channel activity on glucose-dependent 
increases in ISF Aβ, we pharmacologically manipulated hippo-
campal KATP channels under euglycemic and hyperglycemic con-
ditions. We delivered glibenclamide, a KATP channel antagonist, 
to the APP/PS1 hippocampus via reverse microdialysis and found 
that it increased ISF Aβ and lactate levels in a dose-dependent 
manner, with a maximal effect of 36.2% ± 3.2% and 73.3% ± 19.8%, 
respectively (Figure 2, A and B). These findings illustrate that clo-
sure of KATP channels leads to both increased neuronal activity and 
extracellular concentrations of Aβ (Figure 2, A andB). Conversely, 
we investigated whether the KATP channel agonists, diazoxide and 
pinacidil, affect ISF Aβ and lactate levels by opening KATP channels 
Figure 3. Pharmacological manip-
ulation of KATP channels blocks 
hyperglycemia-induced increases 
in ISF Aβ. (A) In 18-month-old 
APP/PS1 mice, glucose clamps 
increase ISF Aβ. However, when 
diazoxide, a KATP agonist, is given 
via reverse microdialysis dur-
ing hyperglycemia, the increase 
in ISF Aβ is blocked (38.84% ± 
3.5% vs. 9.33% ± 2.1% increase). 
(B) Treatment with diazoxide 
decreased hippocampal ISF lactate 
in 18-month-old APP/PS1 mouse 
brains during hyperglycemia, 
suggesting decreased neuronal 
activity coincides with decreased 
ISF Aβ (11.8% ± 3.6% vs. –4.043% 
± 3.4%). Data represent mean 
± SEM. For all analyses, n = 6–7 
mice/group, *P < 0.05, ***P < 
0.001 using 2-way ANOVA.
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models of AD (26), the identification of these channels as a link 
between hyperglycemia and AD pathology creates an avenue for 
translational research in AD.
Methods
Detailed information can be found in Supplemental Methods.
Statistics. Statistical analysis using Student’s t tests, 1-way 
ANOVAs, and 2-way ANOVAs and the appropriate post hoc tests were 
performed as described in each experiment above. P values ≤ 0.05 
were considered significant.
Study approval. All procedures were carried out in accordance 
with an approved IACUC protocol from Washington University 
School of Medicine.
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changes in Aβ, glucose, and lactate within the hippocampal ISF. 
Our data demonstrate that elevated blood glucose levels affect 
hippocampal metabolism, neuronal activity, and ISF Aβ concen-
trations in young mice, lacking any appreciable Aβ plaque load. 
However, in aged mice with marked Aβ deposition, the effect 
of hyperglycemia on ISF Aβ is exacerbated, suggesting that age- 
or pathology-dependent changes result in an alteration of the 
brain’s response to a metabolic insult. Since extracellular Aβ, 
and subsequently tau, aggregate in a concentration-dependent 
manner during the preclinical period of AD while individuals 
are cognitively normal (27), our findings suggest that repeated 
episodes of transient hyperglycemia, such as those found in 
T2DM, could both initiate and accelerate plaque accumulation. 
Thus, the correlation between hyperglycemia and increased ISF 
Aβ provides one potential explanation for the increased risk of 
AD and dementia in T2DM patients or individuals with elevated 
blood glucose levels. In addition, our work suggests that KATP 
channels within the hippocampus act as metabolic sensors and 
couple alterations in glucose concentrations with changes in 
electrical activity and extracellular Aβ levels. Not only does this 
offer one mechanistic explanation for the epidemiological link 
between T2DM and AD, but it also provides a potential thera-
peutic target for AD. Given that FDA-approved drugs already 
exist for the modulation of KATP channels and previous work 
demonstrates the benefits of sulfonylureas for treating animal 
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